Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden Anstalt des öffentlichen Rechts des Freistaates Sachsen
ZKN Logo
  • The Center
    • Multiple Sclerosis Center Dresden
      • Patient Information
      • Contact MSC
      • Physicians & Nurses
      • Study Team
      • Neuropsychology
    • Mobility Center
      • The Mobility Center
      • Walking Assessment
      • Jump Assessment
      • DIERS
      • EMIQ
      • Projects
    • Neuroimmunological Laboratory
      • The NIL
      • Neurofilament light chain
    • Autonomic & Neuroendocrinological Functional Laboratory
      • The ANF
      • ANF Assessment
    • MS Living Lab
    • Management & Science
      • Team Management & Science
      • Projects
      • eHealth & Analytics
        • MSDS 3D
        • MSDS Clinic & Practice
        • MS-HRS
        • MTRS
      • Multiple Sclerosis Management
  • Aktuelles
    • Neuigkeiten
    • Publikationen
    • Veranstaltungen
      • Adventssymposium
      • Multiple Sklerose 360°
      • Welt-MS-Tag 2021
    • Doktorarbeiten
    • Jobs
    • Kontakt
  • Podcasts & Newsletter
    • Newsletter
    • Patienten-Podcast
    • Ärzte-Podcast
    • Neurovision
    • Immune cell calender 25
    • Sherlock-MS-Blog
  • Studien
    • Interventionelle Studien
    • B-SHUTTLE
    • Nicht-interventionelle Studien
    • MS PATHS
    • Konectom
    • Sprachanalyse
English (UK)
Deutsch
English (UK)

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL

MS Treatments

Jahr

Publikationsjahr
2017

Autoren

Autorenliste der Publikation
Alsop J, Medin J, Cornelissen C, Vormfelde SV, Ziemssen T.

Verlag

Publisher-Information
PLoS ONE 2017;12(5).

Link

Zur Publikation (externer Server)
https://doi.org/10.1371/journal.pone.0173353

Tags

Forschungsthemen
Multiple SkleroseMS Behandlung
Treatments2017

  • Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs

    NIL
    Jahr
    2025

  • Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study

    MS Treatments
    Jahr
    2025

  • Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS

    MS Treatments
    Jahr
    2025

  • A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?

    MS Treatments
    Jahr
    2025

  • Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study

    MASC
    Jahr
    2025
  • Start
  • Aktuelles
  • Publikationen
  • MS Treatments
  • Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL
Impressum & Datenschutz

© 2025
Universitätsklinikum C.G. Carus Dresden an der Technischen Universität Dresden